YOUR PARTNERS
IN THE QUEST FOR
BETTER HEALTHCARE
Myriad Life Sciences is a strategic advisory and venture accelerator in the life sciences industry,
partnering with pioneers in the bio-pharmaceutical industry to accelerate the delivery of innovations and medical breakthroughs
WHAT WE DO
We combine global expertise and local insights to address the most complex issues that today's healthcare companies face,
and scout the globe for therapeutic opportunities those which an infusion of capital and strategic guidance will greatly enhance chances of success
Strategic Advisory
-
01
Valuation and Deal Advisory
Asset valuation, deal structuring and investment feasibility analysis
-
02
IPO Advisory
Technical evaluation process support, IPO corporate valuation
-
03
Business Development Advisory
Partnership development, alliance management and transaction execution
Venture Accelerator
-
01
NewCo Creation
We pave the road from scouting therapeutic breakthrough to building the right team,
to cultivate today’s most promising bio ventures -
02
Growth Acceleration
We run tailored programs to navigate our portfolios accelerate through
key R&D and business milestones and value inflection points -
03
Capital Investment and Fundraising
We invest seed and growth capital, manage a series of venture funds,
and lead fundraising campaigns to ensure sustainable growth
OUR PEOPLE
Our cross-functional team of R&D,
Business Development, Corporate Strategy and
Venture Investment bring a balance of expertise
that ensure our partners get ahead of the curve
Brian Sung
Chief Executive Officer
Sunghoon Byun
Executive Vice President
Doohong Park
Ph.D. / Chief Technology Officer
Mina Lee
Managing Director
Hyungkoo Chung
Director
Yohan Kim
Manager
John Wonjoon Cho
Manager
Seongun Kim
Manager
Sa Bin Kim
Manager
Dave Tae-Eun Kim
Manager
Career Highlights
Education
Advisory Board
Ph.D.
Sungsook Lee
Consultant
(Previous) National OncoVenture, Chong Kun Dang, CEREP
Ph.D.
Youngwoo Park
CEO at YBiologics
(Previous) KRIBB, LG Life Sciences
Ph.D.
Byoungchul Lee
CEO at Kanaph Therapeutics
(Previous) Santen, 23andMe, Genentech
M.D., Ph.D.
Wooick Jang
Senior Advisor at CHA Advanced Research Institute
(Previous) SL Bigen, Lilly, MSD, Handok
M.D., Ph.D.
Woochan Son
Professor at Asan Medical Center, Department of Pathology
(Previous) Huntingdon Life Sciences, Medizinische Hochschule Hannover, LG Chem
Ph.D.
Younggeun Shin
Professor at Chungnam National University
(Previous) Genentech, GSK
Ph.D.
Youngjoon Park
CEO at IMDpharm & Professor at Ajou University
(Previous) YUHAN, Samil Pharm, CJ Healthcare
Jungkue Lee
CEO at Bridge Biotherapeutics & Advisor at 3billion
(Previous) OliPass, Rex Bio, GalPharma, Crystal Genomics, LG Chem
Seungtaek Kwon
Managing Director, Hana Financial Investment
Jangsub Lee
Senior General Manager, Hana Financial Investment
(Previous) ILJIN Group
Danil Lee
Managing Director, Mirae Asset Securities
Attorney
Dongkwan Kwon
Head Attorney at Myriad Intellectual Property
(Previous) LG Display, Homeplus
Patent Attorney
Jeonghyun Kim
Head Patent Attorney at IPscent
(Previous) KOREANA Patent firm, ORIGIN Patent & Law firm
OUR EXPERIENCES
Strategic Advisory
We have advised leading biotechs and pharmaceuticals assess commercial value of their portfolio,
pass through the KOSDAQ IPO processes, and explore global partnering opportunities
Valuation and Deal Advisory
IPO Advisory
Business Development Advisory
Venture Accelerator
Avelos Therapeutics
Avelos Therapeutics was founded in September 2021, where Myriad led creation of the company and
invested seed capital upon establishment. Avelos is committed to the design and development of
small molecule therapeutics for Oncology. Avelos is advancing therapeutic targets that are potentially
first-in-class or best-in-class, with strategic focus on synthetic lethality, cell cycle regulation and
undruggable targets
NIO BioPharm
NIO BioPharm was founded in April 2021, where Myriad participated as angel investor.
NIO BioPharm owns three proprietary platform technologies to identify next generation immune
checkpoints targets, discover novel antibodies, and develop antibodies for ADC applications.
As part of Myriad’s accelerator program, Nio BioPharm is focusing on development of novel,
first-in-class therapeutic antibody and bi-specifics in the immuno-oncology space
GET IN TOUCH
To learn more about Myriad Life Sciences, or to discuss a potential partnership,
or investment opportunity, please contact:
Address
Myriad Bldg., 67-11, Nonhyeon-ro 149-gil, Gangnam-gu, Seoul,
06039, of Korea
Phone number
+82 2-2138-6130